

Minerva Neurosciences Inc

COMPANY AND PIPELINE OVERVIEW REPORT

A comprehensive coverage of the company and a summary of the drug pipeline portfolio.

Publication Date: 07-Mar-2015

THOMSON REUTERS

3 Times Square
New York, New York 10036
United States

Tel: +1 646 223 4000

thomsonreuters.com

[Return to Table of Contents](#)



ABOUT COMPANY AND PIPELINE OVERVIEW REPORT

Thomson Reuters provides the knowledge, tools, and expertise to help support drug discovery and development activities, IP portfolio optimization, identification of licensing and partnering opportunities, delivery of successful regulatory submissions, and the ability to keep current with the rapidly-changing pharmaceutical and chemical markets, supporting informed, early decisions.

This report was created by Thomson Reuters, using information from *Thomson Reuters Cortellis™ for Competitive Intelligence*; a comprehensive, proven intelligence solution that leverages the most accurate, complete, and widely respected drug pipeline information. From drug discovery and development activities to patent reports, the latest deals, and partnering opportunities, *Cortellis* can provide the confidence to make the most informed business decisions, faster. *Cortellis for Competitive Intelligence* provides accurate and validated information on pharmaceutical and biotechnology companies globally, their drug pipelines, deals, patents, and clinical trials, plus breaking industry news and conference coverage. All contained in one simple, highly intuitive research platform.

Cortellis Company and Pipeline Overview reports are the first in a series of reports that track pharmaceutical and biotechnology companies worldwide. Further report offerings planned to follow include: Company Detailed Pipeline and Company Competitive Landscape reports. All *Cortellis for Competitive Intelligence* content is subject to the most comprehensive editorial review process available, conducted by scientists, pharma professionals, regulatory experts, and generics specialists. Featuring timely drug pipeline information expertly uncovered and integrated from a significant number of global meetings each year, you'll always be on top of the latest developments.

Chosen by leading life sciences companies, their executives and investors, *Cortellis for Competitive Intelligence* accelerates your deal-making and gives you timely insights on the development landscape.

Discover undiscovered opportunities in drug development and licensing faster with *Thomson Reuters Cortellis™ for Competitive Intelligence*

DISCLAIMER

The information contained in this report is based on sources believed to be correct but Thomson Reuters does not guarantee the accuracy, timeliness, or completeness of this information. Opinions, if any, are those held by the author of any individual report or article at the time of initial publication and do not necessarily reflect the views of Thomson Reuters.

Information in this report on companies is intended for reference use only, and does not constitute a recommendation to buy or sell any particular security or other investment and does not constitute an offer to buy from or sell to any particular investor. Any company or securities mentioned in this report may not be suitable for any particular investor, depending on that investor's financial position and needs.

[Return to Table of Contents](#)



GLOSSARY

Number of Drugs in Active Development

Number of drugs associated with the company or subsidiary that are currently in active development, i.e. the development status for the drug(s) is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended.

Number of Inactive Drugs

Number of drugs associated with the company or subsidiary that are currently classified as inactive, i.e. where the development status for the drug(s) is one of the following: No Development Reported, Discontinued, or Withdrawn.

Number of Patents as Owner

Number of patents associated with the company where the company is listed as owner; i.e. the relationship type (or way the patent refers to the company) is: Patent Assignee/Owner, Patent owner (not assignee), Licensee for development and marketing, Licensee – marketing only (Distributor), Patent assignee of family member, Inferred assignee.

Number of Patents as Third Party

Number of patents associated with the company where the company is listed as third party; i.e. the relationship type (or way the patent refers to the company) is: Patent assignee (not owner), Ex-Licensee for development and marketing, Ex-Licensee marketing only (Distributor), Customer of technology, Ex-Customer of technology, Patent opponent or infringer, Affiliate organization of inventor, Owner of underlying technology.

Patents summary table

This table represents a summary of the core patent coverage for this company covering Therapeutic EP, US and WO patents since 1990 only.

Number of Deals

A count of deals where the company or one of its subsidiaries is the primary company.

Key Indications

Displays top ten key indications for the company and its subsidiaries based on frequency (indications occurring with high and identical frequency are always included, and this may result in more than ten Key Indications being listed). Includes both indications associated with patents where the company is patent owner and indications associated with drugs in active development. A drug is classified as 'active' if it features on a row (or rows) in the current development status table where the status is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended.

Key Target-based Actions

Displays top ten key target-based actions for the company and its subsidiaries based on frequency (actions occurring with high and identical frequency are always included, and this may result in more than ten Key Target-based Actions being listed). Includes both target-based actions associated with patents where the company patent owner and target-based actions associated with drugs in active development. A drug is classified as 'active' if it features on a row (or rows) in the current development status table where the status is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended. A target-based action is one that is associated with a target.

Key Technologies

Displays top ten key technologies for the company and its subsidiaries based on frequency (technologies occurring with high and identical frequency are always included, and this may result in more than ten Key Technologies being listed). Includes both key technologies associated with patents where the company relationship is patent owner and key technologies associated with drugs in active development. A drug is classified as 'active' if it features on a row (or rows) in the current development status table where the status is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended.

[Return to Table of Contents](#)



PLEASE NOTE: the financials section where present in the report includes: Share Information, Stock Performance chart (including the consensus recommendation), and Major Shareholders. Financial Performance presents graphical and tabular data on Worldwide Sales, Operating Income and Net Income over time, together with a Quarterly earnings update. Balance Sheet lists Assets, Liabilities and Stockholders Equity, and Forecasts includes: EPS Forecast and Other Forecasts. The data reported in all sections (except share information and major stock holders) are correct as of the publication date of the report (and not the download date). For share information and major stock holders the data is correct for the date shown with these sections

[Return to Table of Contents](#)



TABLE OF CONTENTS

Company Overview..... 7

Company Profile..... 7

Company Financials..... 7

Product Portfolio Summary..... 11

Product Portfolio Drugs..... 14

[Return to Table of Contents](#)

Minerva Neurosciences Inc

COMPANY OVERVIEW

Company Name	Minerva Neurosciences Inc
Parent Company Name	Minerva Neurosciences Inc
Website	http://minervaneurosciences.com/
Country	US
Number of Drugs in Active Development	5
Number of Inactive Drugs	0
Number of Patents as Owner	3
Number of Patents as Third Party	0
Number of Deals	3
Key Indications	Parkinsons disease,Depression,Schizophrenia,Insomnia,Sleep disorder,Alzheimers disease,Anxiety disorder,Attention deficit-disruptive behaviour disorder,Bipolar disorder,Cognitive disorder,Delusion,Drug dependence,HIV associated dementia,Hallucination,Hyperactivity,Hypomania,Lewy body dementia
Key Target-based Actions	ErbB3 tyrosine kinase receptor modulator,Neuregulin ligand,Orexin 2 receptor antagonist,5-HT 2a receptor antagonist,Opioid receptor sigma antagonist 2,5-HT 1a receptor antagonist
Key Technologies	Biological therapeutic,Formulation solid,Peptide,Small molecule therapeutic,Subcutaneous formulation,Suspension,Systemic formulation

COMPANY PROFILE

SUMMARY

Minerva Neurosciences, formed by the merger of Cyrenaic and SONKEI pharmaceuticals, in November 2013, is focused on the development and commercialization of drugs for the treatment of CNS diseases.

FINANCIAL

In January 2015, the company entered into a \$15 million debt facility with Oxford Finance LLC and Silicon Valley Bank.

In June 2014, Minerva announced its initial public offering of 5,454,545 shares of its common stock priced at \$6.00 per share and at that time, the underwriters were granted a 30-day option to purchase up to 818,181 additional shares of common stock at the same price. The offering was expected to close on July 07, 2014. In July 2014, the shares began trading on the NASDAQ global market under the symbol "NERV". In July 2014, the IPO was completed. By August 2014, the company had also sold approximately 0.7 million shares in a private placement. The net proceeds from the IPO and private placement were approximately \$29.9 million.

COMPANY FINANCIALS

SHARE INFORMATION

Close Price (USD)	5.34
Change (USD)	-0.24 (-4.30%)
Previous Close Price (USD)	5.58
Volume	30,814

[Return to Table of Contents](#)



52-Week High (USD)	10.00
52-Week Low (USD)	4.08
Date	06-Mar-2015
Exchange	NASDAQ(COMPOSITE)
Current Number of Shares Outstanding	18,439,482
Current Market Capitalization	94,778,937
EPS (Date Reported)	-0.06144

STOCK PERFORMANCE




MAJOR SHAREHOLDERS

Shareholder	Type	Country	Shares held	% of shares held	Change in holding	% changes in shares held	Date
Care Capital, LLC	Private Equity	United States	2,869,292	15.56	-1,013,920	-0.26	22-Jan-2015
Fidelity Select Biotechnology Portfolio	Mutual Fund	United States	1,271,400	6.89	0	0	31-Jan-2015
Fidelity Advisor Biotechnology Fund	Mutual Fund	United States	228,600	1.24	0	0	31-Jan-2015

[Return to Table of Contents](#)

The Vanguard Group, Inc.	Investment Advisor	United States	28,547	0.15	26,973	17.14	31-Jan-2015
Vanguard Extended Market Index Fund	Mutual Fund	United States	25,463	0.14	23,889	15.18	31-Jan-2015
Fidelity Spartan Extended Market Index Fund	Mutual Fund	United States	24,020	0.13	0	0	31-Jan-2015
Fidelity NASDAQ Composite Index Fund	Mutual Fund	United States	3,949	0.02	0	0	31-Jan-2015
Vanguard Total Stock Market Index Fund	Mutual Fund	United States	3,084	0.02	3,084	1	31-Jan-2015
AXA/Lord Abbett Micro Cap Portfolio	Mutual Fund	United States	820	0	0	0	31-Jan-2015

FINANCIAL PERFORMANCE



	2011	2012	2013		
Sales (USD M)	0	0	0		
Operating Income (USD M)	-1.127891	-1.581016	-3.160979		
Net Income (USD M)	-1.122714	-1.581955	-3.262005		

[Return to Table of Contents](#)

Quarterly earnings update

Period	Sales (USD M)	Operating Income (USD M)	Net Income (USD M)
2014 Q3	0	-27.151351	-27.155197
2014 Q2	0	-17.649835	-19.365662
2014 Q1	0	-2.623328	-2.938418
2013 Q4	0	-2.02839	-2.126529
2013 Q2	0	-0.378787	-0.375953
2013 Q1	0	-0.27133	-0.27133
2012 Q4	0	-0.2944	-0.296152

BALANCE SHEET

Assets (USD M)

	2011	2012	2013		
Cash & Short Term Investments	0.208857	0.200314	1.818317		
Inventories - Total	0	0	0		
Current Assets - Total	0.243173	0.209309	1.819169		
Property, Plant And Equipment - Net		0	0.003232		
Other Assets - Total	0	0	27.352385		
Total Assets	0.243173	0.209309	29.174786		

Liabilities (USD M)

	2011	2012	2013		
Accounts Payable		0	0.522981		
Short Term Debt & Current Portion Of Long Term Debt	0	0	0.05827		
Current Liabilities - Total	0.130004	0.19029	1.406583		
Long Term Debt	0	0	0		
Deferred Taxes		0	7.5886		
Other Liabilities	0	0	0		
Total Liabilities	0.130004	0.19029	8.995183		

[Return to Table of Contents](#)



Stockholders Equity (USD M)

	2011	2012	2013		
Minority Interest	0	0	0		
Preferred Stock	0	0	0		
Common Stock	0.00112	0.000356	0.000611		
Treasury Stock	0	0			
Total Liabilities & Shareholders' Equity	0.243173	0.209309	29.174786		

FORECASTS

EPS Forecast

Year ending	Current Forecast	1 month ago	3 months ago
31-Dec-2015	-1.96	-1.96	-1.96
31-Dec-2016	-2.57	-2.57	-2.57
31-Dec-2017	-2.49	-2.49	-2.49

Other Forecasts

Year ending	DPS	CPS	Pretax	Sales
31-Dec-2015			-34.36	8.33
31-Dec-2016			-63.68	0
31-Dec-2017			-50.87	15

[Return to Table of Contents](#)




PRODUCT PORTFOLIO SUMMARY

DRUGS

Drugs by Indication

Active Drugs by Indication Chart




Drugs by Indication Table

Indication	Active	Inactive	Total
Neurological disease	3	0	3
Psychiatric disorder	2	0	2
Genetic disorder	1	0	1

[Return to Table of Contents](#)

Drugs by Highest Status

Active Drugs by Highest Status Chart



Drugs by Highest Status Table

Development Status	Number of Drugs
Phase 2 Clinical	1
Phase 1 Clinical	2
Discovery	2

DEALS

Deal Type	Principal		Partner		Total
	Active	Inactive	Active	Inactive	
Drug - Development/Commercialization License	1	0	2	0	3

CLINICAL TRIALS

Trials by Condition Studied

Condition Studied	Ongoing	All
Psychiatric disorder	0	2
Genetic disorder	0	1

[Return to Table of Contents](#)

Trials by Phase

Phase	Ongoing	All
Phase 2	0	1
Phase 1	0	2
Phase not specified	0	1

Phase Definitions

Phase 3 Clinical

Includes Phase 3, Phase 3b, Phase 3a, Phase 2/3 (where enrolment count is 300 or over)

Phase 2 Clinical

Includes Phase 2, Phase 2a, Phase 2b, Phase 1/2 (where enrolment count is 100 or over), Phase 2/3 (where enrolment count is under 300 or not specified)

Phase 1 Clinical

Includes Phase 1, Phase 1a, Phase 1, Phase 1/2 (where enrolment count is under 100 or not specified), Phase 0

PATENTS *

Indication	As Owner	As Third Party	Total
Degeneration	1	0	1
Psychiatric disorder	3	0	3
Genetic disorder	2	0	2
Neurological disease	3	0	3
Toxicity and intoxication	1	0	1

* This table represents a summary of the core patent coverage for this company covering Therapeutic EP, US and WO patents since 1990 only.

[Return to Table of Contents](#)



PRODUCT PORTFOLIO DRUGS

PLEASE NOTE: Highest status refers to highest development of that drug for one of the active companies

MIN-101

Drug Name	MIN-101
Key Synonyms	
Originator Company	Mitsubishi Chemical Holdings Corp
Active Companies	Minerva Neurosciences Inc
Inactive Companies	Mitsubishi Chemical Holdings Corp
Highest Status	Phase 2 Clinical
Active Indications	Schizophrenia
Target-based Actions	5-HT 2a receptor antagonist, Opioid receptor sigma antagonist 2
Other Actions	Antipsychotic
Technologies	Oral formulation, Small molecule therapeutic
Last Change Date	06-Dec-2014

MIN-117

Drug Name	MIN-117
Key Synonyms	
Originator Company	Mitsubishi Pharma Corp
Active Companies	Minerva Neurosciences Inc
Inactive Companies	Mitsubishi Tanabe Pharma Corp, Sonkei Pharmaceuticals Inc, Mitsubishi Pharma Corp
Highest Status	Phase 1 Clinical
Active Indications	Depression
Target-based Actions	5-HT 1a receptor antagonist
Other Actions	Antidepressant, 5-HT uptake inhibitor
Technologies	Systemic formulation unspecified, Small molecule therapeutic
Last Change Date	06-Aug-2014

[Return to Table of Contents](#)



MIN-202

Drug Name	MIN-202
Key Synonyms	
Originator Company	Minerva Neurosciences Inc
Active Companies	Minerva Neurosciences Inc, Janssen Pharmaceutica NV
Inactive Companies	
Highest Status	Phase 1 Clinical
Active Indications	Insomnia
Target-based Actions	Orexin 2 receptor antagonist
Other Actions	
Technologies	Systemic formulation unspecified, Suspension, Small molecule therapeutic, Formulation solid
Last Change Date	23-Jan-2015

MIN-301

Drug Name	MIN-301
Key Synonyms	
Originator Company	ProteoSys AG
Active Companies	Minerva Neurosciences Inc
Inactive Companies	Mind-NRG, ProteoSys AG
Highest Status	Discovery
Active Indications	Parkinsons disease
Target-based Actions	Neuregulin ligand, Erbb3 tyrosine kinase receptor modulator, Erbb4 tyrosine kinase receptor stimulator
Other Actions	Neuroprotectant, Nootropic agent, Antiparkinsonian
Technologies	Injectable formulation, Biological therapeutic, Parenteral formulation unspecified, Peptide
Last Change Date	06-Jan-2015

[Return to Table of Contents](#)

MIN-301 analog (sc, Parkinsons disease), Minerva Neurosciences

Drug Name	MIN-301 analog (sc, Parkinsons disease), Minerva Neurosciences
Key Synonyms	
Originator Company	Minerva Neurosciences Inc
Active Companies	Minerva Neurosciences Inc
Inactive Companies	
Highest Status	Discovery
Active Indications	Parkinsons disease
Target-based Actions	Neuregulin ligand, Erbb3 tyrosine kinase receptor modulator
Other Actions	Antiparkinsonian, Nootropic agent
Technologies	Subcutaneous formulation, Biological therapeutic, Peptide
Last Change Date	06-Jan-2015

This report was created by Thomson Reuters, using information from *Thomson Reuters Cortellis™ for Competitive Intelligence*; a comprehensive, proven intelligence solution that leverages the most accurate, complete, and widely respected drug pipeline information.

For more information about *Cortellis for Competitive Intelligence*, visit:

http://cortellis.thomsonreuters.com/cortellis_for_you/?cid=thomsonone.

For subscription information, e-mail scientific.lifesciences@thomsonreuters.com.

© 2012 Thomson Reuters. All rights reserved.
Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks and trademarks of Thomson Reuters and its affiliated companies.

[Return to Table of Contents](#)

